Lab
Laboratory Corporation of America
Laboratory Corporation of America was paid $103.81M by Medicaid between Jan 2018 and Dec 2024, across 423 billing codes. Its largest line is 81420, Fetal chromosomal aneuploidy genomic sequence analysis panel — 7.2% of everything it billed.
33Billing provider infoLABORATORY CORPORATION OF AMERICA
HOUSTON, TX 77040
HOUSTON, TX 77040
33aNPI1881679751assigned 12/13/2005
33bProvider typeClinical Medical Laboratory
28Total paid$103.81M
24GClaims11,078,864
24DCodes billed423
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#5 of 436
Median peer was paid$17K
This provider vs. median6,018×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 688,805 | $2.72M | |
| 2019 | 658,736 | $2.77M | |
| 2020 | 977,385 | $7.87M | |
| 2021 | 2,342,009 | $24.41M | |
| 2022 | 2,422,436 | $26.15M | |
| 2023 | 2,247,749 | $22.31M | |
| 2024incomplete | 1,741,744 | $17.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 7.2% | 24,082 | 22,998 | $7.51M |
| 80050 | General health panel | 6.7% | 265,914 | 250,589 | $7.01M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.7% | 97,395 | 89,200 | $6.97M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.2% | 304,908 | 279,486 | $6.44M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.2% | 304,269 | 279,150 | $6.41M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.9% | 155,246 | 139,149 | $5.06M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.8% | 274,465 | 256,725 | $3.93M |
| 80081 | 3.5% | 84,069 | 78,452 | $3.62M | |
| 80061 | Lipid panel | 3.3% | 651,473 | 615,774 | $3.40M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.2% | 304,577 | 282,732 | $3.34M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 3.0% | 15,042 | 13,296 | $3.15M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.5% | 128,830 | 117,348 | $2.57M |
411 more codes
| 80053 | Comprehensive metabolic panel | 2.2% | 620,067 | $2.24M |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.1% | 566,820 | $2.22M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.1% | 134,693 | $2.17M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.9% | 354,096 | $1.98M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 643,398 | $1.84M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.5% | 74,305 | $1.57M |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.4% | 360,455 | $1.41M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.2% | 30,598 | $1.24M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.1% | 58,021 | $1.13M |
| 83655 | <1% | 149,239 | $1.03M | |
| 86803 | <1% | 143,037 | $1.01M | |
| 80074 | <1% | 55,359 | $968K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,723 | $776K |
| 87150 | <1% | 39,858 | $769K | |
| 84439 | <1% | 200,758 | $767K | |
| 87536 | <1% | 21,101 | $765K | |
| 86592 | <1% | 232,524 | $560K | |
| 87340 | <1% | 105,928 | $506K | |
| 82607 | <1% | 93,052 | $503K | |
| 84702 | <1% | 60,071 | $500K | |
| 87081 | <1% | 124,391 | $475K | |
| 82728 | <1% | 81,371 | $452K | |
| 86480 | <1% | 15,707 | $444K | |
| 84403 | <1% | 32,633 | $397K | |
| 81329 | <1% | 10,259 | $353K | |
| 87088 | <1% | 99,694 | $346K | |
| 86235 | <1% | 9,938 | $341K | |
| 86762 | <1% | 46,620 | $333K | |
| 87186 | <1% | 93,178 | $327K | |
| 82746 | <1% | 57,487 | $310K | |
| 85027 | <1% | 97,661 | $304K | |
| 82950 | <1% | 113,146 | $303K | |
| 82670 | <1% | 21,574 | $298K | |
| 83970 | <1% | 28,313 | $283K | |
| 84146 | <1% | 29,168 | $281K | |
| 86360 | <1% | 15,107 | $272K | |
| 83525 | <1% | 40,836 | $272K | |
| 83550 | <1% | 76,135 | $271K | |
| 86003 | <1% | 6,641 | $268K | |
| 84436 | <1% | 95,991 | $265K | |
| 83001 | <1% | 28,869 | $262K | |
| 86696 | <1% | 21,451 | $256K | |
| 81001 | <1% | 192,298 | $253K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12,710 | $252K |
| 84481 | <1% | 34,864 | $233K | |
| 86850 | <1% | 51,971 | $233K | |
| 88141 | <1% | 16,571 | $230K | |
| 83540 | <1% | 90,815 | $226K | |
| 82570 | <1% | 132,899 | $225K | |
| 87480 | <1% | 21,205 | $220K | |
| 84153 | <1% | 38,182 | $218K | |
| 83002 | <1% | 23,280 | $216K | |
| 87660 | <1% | 21,170 | $209K | |
| 86780 | <1% | 28,102 | $204K | |
| 82951 | <1% | 28,986 | $204K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 5,653 | $203K |
| 82043 | <1% | 114,140 | $203K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,907 | $195K |
| 84479 | <1% | 66,501 | $185K | |
| 87077 | <1% | 53,505 | $184K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 3,328 | $184K |
| 82533 | <1% | 18,910 | $181K | |
| 87510 | <1% | 21,219 | $179K | |
| 83013 | <1% | 6,416 | $178K | |
| 83498 | <1% | 10,687 | $177K | |
| 84402 | <1% | 13,780 | $167K | |
| 84144 | <1% | 15,234 | $166K | |
| 87522 | Neg quan hep c or qual rna | <1% | 7,958 | $162K |
| 86038 | <1% | 31,190 | $162K | |
| 86706 | <1% | 29,618 | $160K | |
| 86376 | <1% | 21,838 | $158K | |
| 82157 | <1% | 8,532 | $156K | |
| 86695 | <1% | 19,201 | $149K | |
| 82627 | <1% | 14,131 | $149K | |
| 86704 | <1% | 26,525 | $146K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,538 | $140K |
| 84480 | <1% | 24,177 | $134K | |
| 86787 | <1% | 18,476 | $132K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 46,562 | $121K |
| 83735 | <1% | 58,334 | $117K | |
| 82947 | <1% | 65,279 | $113K | |
| 87902 | <1% | 874 | $111K | |
| 83880 | <1% | 12,953 | $110K | |
| 86361 | <1% | 9,508 | $109K | |
| 82105 | <1% | 14,749 | $109K | |
| 82274 | <1% | 15,802 | $108K | |
| 87070 | <1% | 26,625 | $107K | |
| 86140 | <1% | 53,953 | $106K | |
| 88142 | <1% | 8,571 | $106K | |
| 87625 | <1% | 4,719 | $104K | |
| 86800 | <1% | 11,616 | $96K | |
| 83020 | <1% | 13,605 | $95K | |
| 86769 | <1% | 3,150 | $93K | |
| 82024 | <1% | 4,063 | $87K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 945 | $81K |
| 84550 | <1% | 55,420 | $81K | |
| 80055 | <1% | 2,329 | $78K | |
| 80076 | <1% | 21,122 | $76K | |
| 82784 | <1% | 13,288 | $76K | |
| 82652 | <1% | 9,102 | $76K | |
| 86901 | <1% | 47,400 | $70K | |
| 86900 | <1% | 47,409 | $70K | |
| 82565 | <1% | 39,713 | $69K | |
| 82248 | <1% | 35,973 | $68K | |
| 84156 | <1% | 49,823 | $64K | |
| 85652 | <1% | 61,508 | $64K | |
| 82977 | <1% | 25,175 | $63K | |
| 86665 | <1% | 3,474 | $62K | |
| 82952 | <1% | 27,301 | $59K | |
| 85660 | <1% | 19,039 | $59K | |
| 81243 | <1% | 6,910 | $58K | |
| 86431 | <1% | 23,984 | $58K | |
| 84450 | <1% | 32,132 | $57K | |
| 86300 | <1% | 5,229 | $55K | |
| 86225 | <1% | 10,538 | $55K | |
| 85610 | <1% | 37,547 | $54K | |
| 84100 | <1% | 41,007 | $54K | |
| 80069 | <1% | 25,596 | $52K | |
| 82247 | <1% | 32,657 | $52K | |
| 86708 | <1% | 9,738 | $52K | |
| 85018 | <1% | 35,478 | $51K | |
| 86794 | <1% | 5,689 | $51K | |
| 86317 | <1% | 7,530 | $51K | |
| 87209 | <1% | 5,753 | $51K | |
| 84681 | <1% | 5,213 | $50K | |
| 81003 | <1% | 51,991 | $50K | |
| 86677 | <1% | 7,061 | $50K | |
| 83615 | <1% | 24,505 | $48K | |
| 85730 | <1% | 22,251 | $47K | |
| 80164 | <1% | 9,377 | $47K | |
| 84305 | <1% | 3,699 | $47K | |
| 81361 | <1% | 956 | $47K | |
| 83690 | <1% | 15,441 | $46K | |
| 84460 | <1% | 22,071 | $44K | |
| 84520 | <1% | 31,498 | $44K | |
| 86200 | <1% | 8,643 | $44K | |
| 82378 | <1% | 7,543 | $43K | |
| 82785 | <1% | 4,757 | $43K | |
| 86160 | <1% | 6,728 | $42K | |
| 83021 | <1% | 3,894 | $42K | |
| 85060 | <1% | 3,970 | $42K | |
| 84075 | <1% | 27,769 | $40K | |
| 86147 | <1% | 1,411 | $40K | |
| 82040 | <1% | 28,397 | $40K | |
| 82239 | <1% | 4,360 | $40K | |
| 82310 | <1% | 26,377 | $38K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,556 | $38K |
| 83520 | <1% | 4,685 | $37K | |
| 88342 | <1% | 1,175 | $37K | |
| 82150 | <1% | 12,811 | $36K | |
| 82550 | <1% | 19,103 | $35K | |
| 88341 | <1% | 1,008 | $35K | |
| 84295 | <1% | 24,476 | $34K | |
| 84445 | <1% | 1,113 | $33K | |
| 82435 | <1% | 25,569 | $33K | |
| 84155 | <1% | 29,110 | $32K | |
| 85045 | <1% | 18,082 | $31K | |
| 86870 | <1% | 3,114 | $30K | |
| 87427 | <1% | 4,942 | $30K | |
| 86364 | <1% | 3,460 | $29K | |
| 84132 | <1% | 21,732 | $29K | |
| 87177 | <1% | 5,740 | $27K | |
| 80348 | <1% | 2,177 | $27K | |
| 86146 | <1% | 1,038 | $27K | |
| 84703 | <1% | 6,107 | $27K | |
| 82677 | <1% | 1,794 | $26K | |
| 83516 | <1% | 4,366 | $26K | |
| 80197 | <1% | 11,871 | $25K | |
| 86593 | <1% | 11,585 | $25K | |
| 87046 | <1% | 4,933 | $24K | |
| 80361 | <1% | 2,637 | $24K | |
| 87045 | <1% | 4,890 | $24K | |
| 86304 | <1% | 3,621 | $24K | |
| 86664 | <1% | 2,698 | $24K | |
| 84270 | <1% | 2,170 | $23K | |
| 82140 | <1% | 4,897 | $23K | |
| 86341 | <1% | 959 | $22K | |
| 86765 | <1% | 3,729 | $22K | |
| 80177 | <1% | 4,173 | $21K | |
| 84154 | <1% | 3,850 | $21K | |
| 87075 | <1% | 5,749 | $20K | |
| 84134 | <1% | 3,579 | $20K | |
| 86336 | <1% | 1,900 | $18K | |
| 80051 | <1% | 8,242 | $18K | |
| 86735 | <1% | 3,005 | $17K | |
| 87535 | <1% | 1,111 | $17K | |
| 86709 | <1% | 3,510 | $17K | |
| 80349 | <1% | 1,557 | $16K | |
| 84478 | <1% | 8,864 | $16K | |
| 82465 | <1% | 6,986 | $16K | |
| 86141 | <1% | 4,187 | $16K | |
| 85014 | <1% | 11,392 | $15K | |
| 82672 | <1% | 1,254 | $15K | |
| 86334 | <1% | 3,052 | $14K | |
| 84165 | <1% | 6,015 | $14K | |
| 87529 | <1% | 605 | $13K | |
| 81025 | <1% | 3,058 | $13K | |
| 84425 | <1% | 1,472 | $13K | |
| 80365 | <1% | 1,876 | $13K | |
| 82626 | <1% | 902 | $13K | |
| 80354 | <1% | 1,742 | $12K | |
| 87184 | <1% | 3,243 | $12K | |
| 80324 | <1% | 1,299 | $12K | |
| 82575 | <1% | 2,168 | $12K | |
| 83721 | <1% | 4,675 | $12K | |
| 86060 | <1% | 3,567 | $12K | |
| 80202 | <1% | 2,221 | $12K | |
| 85246 | <1% | 875 | $12K | |
| 80156 | <1% | 2,859 | $12K | |
| 81257 | <1% | 925 | $11K | |
| 81209 | <1% | 944 | $10K | |
| 80183 | <1% | 1,417 | $10K | |
| 86702 | <1% | 1,632 | $10K | |
| 85245 | <1% | 739 | $10K | |
| 82374 | <1% | 5,709 | $10K | |
| 84432 | <1% | 1,214 | $9K | |
| 84166 | <1% | 1,837 | $9K | |
| 83521 | <1% | 1,579 | $9K | |
| 80185 | <1% | 3,085 | $9K | |
| 80178 | <1% | 3,292 | $9K | |
| 86258 | <1% | 850 | $9K | |
| 87900 | <1% | 122 | $9K | |
| 86381 | <1% | 795 | $9K | |
| 85240 | <1% | 815 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 221,870 | $9K |
| 87563 | <1% | 545 | $8K | |
| 87210 | <1% | 2,758 | $8K | |
| 83090 | <1% | 2,993 | $8K | |
| 84244 | <1% | 647 | $8K | |
| 85384 | <1% | 1,716 | $8K | |
| 80346 | <1% | 795 | $8K | |
| 82330 | <1% | 2,291 | $8K | |
| 86705 | <1% | 1,901 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 359 | $7K |
| 80373 | <1% | 1,355 | $7K | |
| 86777 | <1% | 1,037 | $7K | |
| 80353 | <1% | 1,421 | $7K | |
| 80358 | <1% | 1,359 | $7K | |
| 87799 | <1% | 2,532 | $7K | |
| 87662 | <1% | 233 | $7K | |
| 85379 | <1% | 1,860 | $7K | |
| 80359 | <1% | 1,362 | $7K | |
| 86301 | <1% | 1,457 | $6K | |
| 80347 | <1% | 839 | $6K | |
| 82103 | <1% | 897 | $6K | |
| 82390 | <1% | 1,143 | $6K | |
| 86337 | <1% | 472 | $6K | |
| 87901 | <1% | 44 | $6K | |
| 86008 | <1% | 112 | $6K | |
| 84590 | <1% | 988 | $6K | |
| 80372 | <1% | 1,248 | $6K | |
| 86015 | <1% | 978 | $6K | |
| 80299 | <1% | 424 | $6K | |
| 82397 | <1% | 785 | $6K | |
| 87497 | <1% | 797 | $6K | |
| 81374 | <1% | 422 | $6K | |
| 86701 | <1% | 1,457 | $6K | |
| 84482 | <1% | 864 | $6K | |
| 84630 | <1% | 1,069 | $6K | |
| 84466 | <1% | 1,366 | $5K | |
| 87517 | <1% | 360 | $5K | |
| 82542 | <1% | 813 | $5K | |
| 87329 | <1% | 821 | $5K | |
| 86037 | <1% | 389 | $5K | |
| 87420 | <1% | 625 | $5K | |
| 88112 | <1% | 187 | $5K | |
| 83527 | <1% | 614 | $5K | |
| 82985 | <1% | 1,180 | $5K | |
| 86644 | <1% | 747 | $5K | |
| 80175 | <1% | 729 | $4K | |
| 81255 | <1% | 944 | $4K | |
| 86645 | <1% | 598 | $4K | |
| 80184 | <1% | 1,121 | $4K | |
| 84207 | <1% | 352 | $4K | |
| 85048 | <1% | 3,032 | $4K | |
| 81251 | <1% | 944 | $4K | |
| 81200 | <1% | 944 | $4K | |
| 84143 | <1% | 261 | $4K | |
| 86663 | <1% | 588 | $4K | |
| 81330 | <1% | 943 | $4K | |
| 88164 | <1% | 551 | $4K | |
| 87521 | Neg quan hep c or qual rna | <1% | 162 | $4K |
| 87906 | <1% | 44 | $4K | |
| 81596 | <1% | 305 | $4K | |
| 85041 | <1% | 1,941 | $4K | |
| 87350 | <1% | 1,148 | $3K | |
| 83921 | <1% | 731 | $3K | |
| 82747 | <1% | 581 | $3K | |
| 82232 | <1% | 509 | $3K | |
| 87324 | <1% | 833 | $3K | |
| 80165 | <1% | 536 | $3K | |
| 80320 | <1% | 237 | $3K | |
| 81260 | <1% | 943 | $3K | |
| 83010 | <1% | 730 | $3K | |
| 81290 | <1% | 944 | $3K | |
| 83014 | <1% | 914 | $3K | |
| 82610 | <1% | 519 | $3K | |
| 86682 | <1% | 997 | $3K | |
| 83883 | <1% | 1,480 | $3K | |
| 84446 | <1% | 386 | $3K | |
| 82553 | <1% | 654 | $3K | |
| 81242 | <1% | 944 | $3K | |
| 84378 | <1% | 725 | $3K | |
| 87338 | <1% | 439 | $3K | |
| 87040 | <1% | 707 | $3K | |
| 86231 | <1% | 475 | $3K | |
| 86778 | <1% | 364 | $3K | |
| 82088 | <1% | 120 | $3K | |
| 80337 | <1% | 519 | $2K | |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | <1% | 924 | $2K |
| 84484 | <1% | 729 | $2K | |
| 86308 | <1% | 851 | $2K | |
| 86707 | <1% | 680 | $2K | |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | <1% | 871 | $2K |
| 85004 | <1% | 863 | $2K | |
| 82634 | <1% | 106 | $2K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 899 | $2K |
| 87807 | <1% | 255 | $2K | |
| 85007 | <1% | 1,592 | $2K | |
| 83992 | <1% | 527 | $2K | |
| 85613 | <1% | 379 | $2K | |
| 83935 | <1% | 623 | $2K | |
| 82166 | <1% | 114 | $2K | |
| 83930 | <1% | 594 | $2K | |
| 87205 | <1% | 1,722 | $2K | |
| 84080 | <1% | 314 | $2K | |
| 86694 | <1% | 205 | $2K | |
| 82787 | <1% | 204 | $2K | |
| 83695 | <1% | 261 | $1K | |
| 80356 | <1% | 95 | $1K | |
| 82340 | <1% | 443 | $1K | |
| 85598 | <1% | 152 | $1K | |
| 82668 | <1% | 246 | $1K | |
| 86880 | <1% | 434 | $1K | |
| 80235 | <1% | 110 | $1K | |
| 86255 | <1% | 158 | $1K | |
| 88312 | <1% | 30 | $1K | |
| 80201 | <1% | 141 | $922.08 | |
| 80364 | <1% | 467 | $889.50 | |
| 82104 | <1% | 100 | $884.61 | |
| 82552 | <1% | 153 | $826.10 | |
| 82085 | <1% | 155 | $809.98 | |
| 80367 | <1% | 464 | $785.03 | |
| 80338 | <1% | 464 | $725.61 | |
| 80355 | <1% | 467 | $708.33 | |
| 80368 | <1% | 465 | $706.93 | |
| 89055 | <1% | 435 | $706.41 | |
| 80357 | <1% | 462 | $705.12 | |
| 80370 | <1% | 464 | $703.34 | |
| 80344 | <1% | 464 | $687.66 | |
| 80326 | <1% | 465 | $683.40 | |
| 80360 | <1% | 464 | $678.23 | |
| 80371 | <1% | 465 | $657.01 | |
| 87650 | <1% | 54 | $654.60 | |
| 80334 | <1% | 464 | $645.87 | |
| 82525 | <1% | 122 | $638.92 | |
| 86256 | <1% | 79 | $626.12 | |
| 80377 | <1% | 462 | $625.10 | |
| 80366 | <1% | 467 | $623.22 | |
| 87481 | <1% | 23 | $601.44 | |
| 80331 | <1% | 464 | $594.77 | |
| 80162 | <1% | 627 | $581.03 | |
| 80341 | <1% | 470 | $580.53 | |
| 83789 | <1% | 84 | $510.93 | |
| 82172 | <1% | 409 | $492.92 | |
| 85670 | <1% | 148 | $467.05 | |
| 85415 | <1% | 211 | $447.54 | |
| 82107 | <1% | 12 | $415.41 | |
| 80321 | <1% | 12 | $375.64 | |
| 80159 | <1% | 60 | $351.55 | |
| 87206 | <1% | 113 | $336.40 | |
| 83993 | <1% | 30 | $334.62 | |
| 82379 | <1% | 29 | $309.88 | |
| 84300 | <1% | 181 | $304.30 | |
| 82633 | <1% | 13 | $303.10 | |
| 86335 | <1% | 80 | $300.44 | |
| 87076 | <1% | 78 | $275.23 | |
| 82725 | <1% | 156 | $271.43 | |
| 87255 | <1% | 12 | $253.74 | |
| 36416 | <1% | 4,232 | $248.95 | |
| 87538 | <1% | 16 | $244.80 | |
| 85306 | <1% | 13 | $193.80 | |
| 84152 | <1% | 53 | $192.27 | |
| 85049 | <1% | 116 | $187.75 | |
| 81015 | <1% | 88 | $174.25 | |
| 80158 | <1% | 28 | $168.42 | |
| 83003 | <1% | 14 | $168.28 | |
| 82679 | <1% | 12 | $156.14 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,754 | $154.71 |
| 86747 | <1% | 13 | $151.51 | |
| 86162 | <1% | 28 | $137.11 | |
| 82540 | <1% | 41 | $110.12 | |
| 85303 | <1% | 13 | $93.28 | |
| 80203 | <1% | 12 | $82.89 | |
| 81291 | <1% | 14 | $79.92 | |
| 87207 | <1% | 14 | $78.26 | |
| 83718 | <1% | 13 | $62.69 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 5,346 | $51.48 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 8,350 | $51.44 |
| 83704 | <1% | 26 | $50.96 | |
| 81241 | <1% | 12 | $45.40 | |
| 86005 | <1% | 13 | $43.99 | |
| 86359 | <1% | 12 | $39.13 | |
| 89060 | <1% | 64 | $34.45 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 16 | $25.12 |
| 89051 | <1% | 53 | $20.14 | |
| 99199 | Unlisted special service, procedure or report | 0% | 39 | $0.00 |
| 81479 | Unlisted molecular pathology procedure | 0% | 34 | $0.00 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 0% | 1,588 | $0.00 |
| S3600 | Stat laboratory request (situations other than s3601) | 0% | 228 | $0.00 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KIMBERLY (VP)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.